Paul F. Schellhammer, MD

Paul F. Schellhammer, MD, a member of the Urology Times editorial council, is professor of urology and program director of the Virginia Prostate Center of the Eastern Virginia Medical School and Sentara Cancer Institute, Norfolk.

Articles by Paul F. Schellhammer, MD

Bladder cancer studies help pinpoint risk of recurrence

ByPaul F. Schellhammer, MD

August 15th 2004

Progression-free curves for N0 disease were improved when more than eight to 10 nodes per side were removed.

Data shed light on salvage RT, immediate hormone Tx

ByPaul F. Schellhammer, MD

August 15th 2004

I believe the evidence is accumulating in favor of earlier [androgen deprivation] therapy to provide a survival benefit.

Latest Updated Articles

Bladder cancer studies help pinpoint risk of recurrence
Published: August 15th 2004 | Updated:
Data shed light on salvage RT, immediate hormone Tx
Published: August 15th 2004 | Updated:

Paul F. Schellhammer, MD

Articles by Paul F. Schellhammer, MD

Bladder cancer studies help pinpoint risk of recurrence

Data shed light on salvage RT, immediate hormone Tx

Latest Updated Articles

Trending on Urology Times

Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC

SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort

Choosing salvage therapy after prostate cancer focal ablation

NDV-01 produces robust 9-month results in high-risk NMIBC

SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use